Compugen (NASDAQ:CGEN) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Compugen Ltd. (NASDAQ:CGEN) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.08 and traded as high as $2.20. Compugen shares last traded at $2.10, with a volume of 242,438 shares traded.

Analysts Set New Price Targets

Several research firms have issued reports on CGEN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. Truist Financial upgraded Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Leerink Partners lowered their price target on Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, May 21st. Lake Street Capital assumed coverage on Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Wall Street Zen cut Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Compugen Stock Performance

The firm has a market cap of $198.56 million, a price-to-earnings ratio of 5.68 and a beta of 2.74. The business has a fifty day moving average of $2.61 and a two-hundred day moving average of $2.08.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Compugen had a net margin of 47.97% and a return on equity of 47.72%. The company had revenue of $2.18 million during the quarter, compared to analysts’ expectations of $1.57 million. On average, equities research analysts forecast that Compugen Ltd. will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Compugen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank Hapoalim BM purchased a new stake in Compugen in the 4th quarter valued at approximately $37,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Compugen in the 4th quarter valued at approximately $38,000. Franklin Resources Inc. purchased a new stake in Compugen in the 2nd quarter valued at approximately $56,000. Calamos Advisors LLC purchased a new stake in Compugen in the 1st quarter valued at approximately $63,000. Finally, Hillsdale Investment Management Inc. purchased a new stake in Compugen in the 1st quarter valued at approximately $68,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.